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DRUG SAFETY EVALUATION
Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with
hypoparathyroidism
Gemma Marcucci a, Giuseppe Della Pepab and Maria Luisa Brandia
aBone Metabolic Diseases Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy; bDepartment of Clinical
Medicine and Surgery, Federico II University, Naples, Italy
ABSTRACT
Introduction: Hypoparathyroidism is a rare disorder characterized by low serum calcium levels and
high serum phosphate levels, and low or inappropriately normal levels of parathyroid hormone (PTH).
This disease is commonly treated with calcium supplements and active vitamin D metabolites or
analogues, but large doses of these supplements are often utilized to relieve the symptoms caused
by hypocalcemia, without guarantee of a physiological normalization of calcium-phosphate
homeostasis.
Areas covered: Several studies have investigated replacement therapy with recombinant human PTH
[rhPTH (1-84) and rhPTH (1-34)] for subjects with hypoparathyroidism. In 2015, The Food and Drug
Administration (FDA) approved, in the United States, rhPTH (1–84), named Natpara®, a bioenginerred
rhPTH, for the management of chronic hypoparathyroidism not well controlled with conventional
therapy. This article evaluates the safety and tolerability of rhPTH (1–84) in patients with chronic
hypoparathyroidism, and also describes the studies conducted so far on rhPTH (1-34) used for chronic
hypoparathyroidism.
Expert opinion: The research done in this field has shown that replacement treatment with rhPTH is an
attractive option for subjects with hypoparathyroidism who are unable to maintain stable and safe
serum and urinary calcium levels. However, since therapy with rhPTH is a long-term management
option in hypoparathyroidism, more long-term safety data are needed.
ARTICLE HISTORY
Received 3 November 2016
Accepted 22 March 2017
KEYWORDS
Hypoparathyroidism;
hypocalcemia; parathyroid
hormone; rhPTH (1-84);
teriparatide; safety
1. Introduction
Hypoparathyroidism is a rare disorder characterized by low
serum calcium levels and high serum phosphate levels due
to absent or inappropriately low parathyroid hormone (PTH)
levels [1]. This disorder can be acquired or hereditary. It results
from a surgical procedure in approximately 75% of patients
and in the remainder is due to genetic, autoimmune, or idio-
pathic etiologies [1,2]. Hypoparathyroidism is commonly trea-
ted with calcium supplements and active vitamin D
metabolites or analogs, but often large doses of these supple-
ments are utilized to relieve the symptoms caused by hypo-
calcemia, without guarantee of a physiological normalization
of calcium-phosphate homeostasis [3]. Even when conven-
tional therapy is able to normalize serum calcium concentra-
tions, patients can suffer from reduced quality of life, muscle
complaints (including fatigue and weakness), and anxiety and
tendency to depression, in addition to the risks of many long-
term complications, such as nephrolithiasis, nephrocalcinosis,
renal impairment, cataracts, and cerebral calcifications [3].
2. A new era for chronic management of
hypoparathyroidism: PTH peptides
Over the past two decades, several studies have investigated
replacement therapy with recombinant human PTH [rhPTH (1-
84)] and with the N-terminal PTH fragment, teriparatide,
[rhPTH (1-34)]. These drugs are administered by subcutaneous
injection and have different pharmacokinetics; rhPTH (1-84) is
administered once daily, while rhPTH (1-34) is administered by
single/multiple injection/s per day or via pump delivery [4,5].
In 2015, The Food and Drug Administration (FDA) approved
rhPTH (1-84), named Natpara®, a bioenginerred rhPTH, for the
management of hypoparathyroidism, only in the USA [6]. It is
produced by recombinant DNA technology using a strain of
Escherichia coli. A recent guideline, published in 2016, recom-
mends taking into consideration rhPTH (1-84) therapy in any
patient with well-established chronic hypoparathyroidism of
any etiology, except for autosomal dominant hypocalcemia
(ADH) type 1 and, in particular, in case of: variable and incon-
stant control of the serum calcium with frequent episodes of
hypo- and hypercalcemia; oral calcium/vitamin D medications
required to control the serum calcium or symptoms that
exceed 2.5 g of calcium or >1.5 μg of active vitamin D;
hypercalciuria, renal stones, nephrocalcinosis, stone risk, or
reduced creatinine clearance or estimated glomerular filtration
rate (eGFR <60m/min), hyperphosphatemia and/or calcium-
phosphate product that exceeds 55 mg2dL2 (4.4 mmol2L2);
gastrointestinal tract disorder that is associated with malab-
sorption; and, finally, reduced quality of life [3]. Natpara® has
not been studied in patients affected by hypoparathyroidism
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with calcium-sensing receptor (CaSR) mutations, because
these patients may have normal levels of PTH but hypocalce-
mia, representing a steady state of the abnormally sensitive
CaSR. In these cases, future therapies might employ calcilytics,
which directly modulate the CaSR. In particular, these mole-
cules bind in the HH (heptahelical) (see Box 1) domain and
suppress CaSR signaling, and at the level of parathyroid
glands, calcilytics promote PTH secretion by reversing the
inhibitory action of the CaSR. Several classes of calcilytics, as
negative modulators of the CaSR, have been developed, and
therapeutic attempts using calcilytics to treat ADH type 1,
caused by heterozygous activating mutations in the CASR,
are currently under investigation [7].
2.1. rhPTH (1-84) hormone replacement therapy in
chronic hypoparathyroidism and its drug safety
evaluation
rhPTH (1-84) is a molecule of 84 amino acids, identical to the
full-length human protein. It is produced by recombinant DNA
technology using a strain of Escherichia coli [6].
Therapy with rhPTH (1-84) increases plasma calcium con-
centrations in a dose-related manner. After a single subcuta-
neous injection, the mean peak serum calcium level is reached
between 10 and 12 h. Then, the increase of serum calcium
above baseline is maintained for more than 24 h. At 12 h, the
maximum mean increases of serum calcium reported are
about 0.5 mg/dl and 0.7 mg/dl from baseline, respectively,
with a dose of 50 and 100 mcg [6]. The drug is supposed to
be administered as a once-a-day subcutaneous injection in the
thigh with a starting dose of 50 mg. At the time of initiation of
therapy, daily dose of active vitamin D is reduced by 50%, and
serum calcium levels are monitored once or twice a week.
According to a predefined schedule, daily dose of active vita-
min D and calcium supplements may be further reduced
according to serum calcium measurement. The dose of
rhPTH (1-84) can be down-titrated to a daily dose of 25 mg
or up-titrated to a daily injection of either 75 or 100 mg [6].
The apparent terminal half-life (t1/2) is 3.02 and 2.83 h,
respectively, for doses with 50 and 100 mcg. The peak plasma
concentrations (mean Tmax) of rhPTH (1-84), for doses of 50
and 100 mcg in patients with hypoparathyroidism, occurs
within 5–30 min, followed by a second, usually smaller, peak
at 1–2 h. The area under the curve (AUC) increased in a dose-
proportional manner from 50 to 100 mcg. The bioavailability is
53%, and in vitro and in vivo studies have shown that the
clearance of PTH hormone is mostly by a hepatic process and,
to a lesser extent, by renal process [6]. No dose adjustment for
this drug is recommended in patients with mild to moderate
hepatic impairment, and no studies have been conducted in
patients with severe renal impairment or in renal impairment
patients on dialysis [6].
It has been demonstrated that this drug permits major
reductions in the need for calcium and active vitamin D meta-
bolites or analog supplements, maintaining normal calcium
concentrations in patients affected by chronic hypoparathyr-
oidism. So far, the studies conducted on rhPTH (1-84) as
hormone replacement therapy for chronic hypoparathyroid-
ism have shown an improvement of calcium homeostasis,
maintaining serum calcium in the normal range, and a trend
to the reduction of 24-h calcium excretion, although this last
outcome has not always been achieved [8–14]. Some studies
also tested the hypothesis that rhPTH (1-84) therapy in chronic
hypoparathyroidism could be associated with improvement in
quality of life measures. In particular, a study evaluated 69
hypoparathyroid subjects, treated with rhPTH (1-84) for a
period of 5 years, through the use of RAND 36-Item Short
Form (SF-36) Health Survey, a measure of health-related qual-
ity of life, which the subjects completed before and during
therapy with rhPTH (1–84) [15]. Most subjects maintained
serum calcium values of at least 8.0 mg/dL throughout the
study period. The subjects showed significant improvement in
the overall score at 2 months that persisted for 5 years. The
authors concluded that rhPTH (1-84) therapy is associated with
improvement in mental and physical health as determined by
the SF-36 metric; however, the limit of this study is that there
is not a placebo group [15]. On the other hand, a placebo-
controlled study conducted on 62 patients with chronic hypo-
parathyroidism did not demonstrate improvement in quality
of life, although a high frequency of hypercalcemic episodes
among these patients may have compromised the potential
beneficial effects of reversing the state of PTH insufficiency
[16]. Since few data exist characterizing the potential effects of
rhPTH therapy to ameliorate quality of life measures, in future
studies, tests should be performed to confirm the potential
positive association between treatment with rhPTH (1-84) and
this important aspect of life for patients with hypoparathyr-
oidism. Therapy with rhPTH (1-84) also promotes the reverse
of the state of low bone turnover, typical of hypoparathyroid-
ism, increasing bone turnover, and seems to promote the
restoration of normal bone physiology [17]. However, more
data are clearly needed in order to understand the long-term
effects of rhPTH (1-84) on BMD (bone mineral density)
changes, bone quality, and risk of fractures. Finally, this drug
has a potential preventive role for other complications includ-
ing nephrolithiasis, nephrocalcinosis, cataracts, and cerebral
calcifications [9–14].
Below, there is a comprehensive analysis of results on drug
safety profile found in papers published from 2010 until now.
The major findings regarding effects on serum and urinary
calcium levels and reduction of calcium and calcitriol supple-
mentation of all clinical studies conducted with rhPTH (1-84)
are summarized in Table 1.
Rubin et al. described the use of the rhPTH (1-84) in a fixed
dose of 100 μg every other day by subcutaneous injection in
Box 1. Drug summary.
Drug name (generic) Recombinant human PTH (1-84)
Phase (for indication under
discussion)
Launched
Indication (specific to discussion) Hypoparathyroidism
Pharmacology description/
mechanism of action
Parathyroid hormone receptor 1
agonist
Route of administration Subcutaneous injection
Chemical structure
Pivotal trial(s) REPLACE, REPEAT; RACE (active, not
recruiting)
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30 patients with hypoparathyroidism in an open-label study
conducted for 24 months. Transient, mild hypercalcemia
occurred sporadically, and not time- or dose-dependent; how-
ever, blood sampling was performed only 48 h after the last
PTH injection, and therefore other episodes with hypercalce-
mia might have been missed [10].
Sikjaer et al. published the data derived from a randomized,
controlled, double-blind study, in which rhPTH (1-84) or pla-
cebo was administrated in a fixed dose of 100 μg in 62
patients for 24 weeks [9]. Treatment with rhPTH (1-84) resulted
in episodes of hypercalcemia during titration, but, compared
with treatment with active vitamin D metabolites, hypercalce-
mic symptoms reportedly were less pronounced and of
shorter duration. Renal function remained stable, and there
was no difference between groups in the occurrence of ser-
ious adverse effects. Infections, musculoskeletal aches, par-
esthesias, and headache followed by cardiovascular
complaints were the most common complaints described,
but only nausea occurred with a significantly higher frequency
in the group treated with rhPTH (1-84) than in the placebo
group. Eight severe adverse events were described, among
which five occurred in the group treated with rhPTH (1-84)
and three in the placebo-group. Two significant adverse
events, requiring hospitalization, were due to hypercalcemia
and hypocalcemia, respectively [9].
Cusano et al. described the effect of 4 years of rhPTH
(1-84) treatment, administered at a starting dose of 100 μg
subcutaneous every other day, in 27 adults affected by chronic
hypoparathyroidism.
Hypercalcemia was uncommon (11 episodes in 8 subjects over
4 years; 1.9% of all values), with most episodes occurring within
the first 6 months and resolving with adjustment of supplemental
calcium and vitamin D. No hypercalcemic events required hospi-
talization. Blood sampling was performed 48 h after the last PTH
injection. Musculoskeletal, gastrointestinal, and genitourinary
complaints were the most common adverse events described.
Other adverse events included: two fractures [the fracture sites
were: elbow (year 1); toe (year 4)] and one episode of nephro-
lithiasis [11].
In REPLACE [“Efficacy and safety of recombinant human
parathyroid hormone (1-84) in hypoparathyroidism”], a dou-
ble-blind, placebo-controlled, randomized phase 3 study,
134 patients with chronic hypoparathyroidism were ran-
domly assigned to 50 μg per day of rhPTH (1-84), but
could be titrated up from 50 to 75 μg and then 100 μg
(weeks 0–5), or placebo for 24 weeks (with a randomization
scheme of 2:1, drug:placebo) [12]. The primary end point
was the proportion of patients at 24 weeks who achieved a
50% or greater reduction from baseline in their daily dose
of oral calcium and active vitamin D with maintenance of
the serum calcium. This end point was met in over half of
the study subjects and in virtually none of the subjects who
received placebo. The overall incidence of adverse events
was similar in both groups. Serious adverse events were
described in 10 (11%) of the patients in the rhPTH (1-84)
group and 4 (9%) in the placebo group. In the group
treated with rhPTH (1-84), only one serious adverse event
due to hypercalcemia was reported. In both groups, no
adverse events regarding cardiovascular or renal
manifestations were described. During maintenance period
(weeks 16–24), a smaller proportion of patients treated with
rhPTH (1-84) reported clinical symptoms associated with
hypocalcemia than did those in the placebo group [12].
Subsequently, another study, called REPEAT [“An open-
label extension study of parathyroid hormone rhPTH(1-84) in
adults with hypoparathyroidism”], has been conducted as a
24-week, open-label, flexible-dose extension study of REPLACE
[13]. Patients previously completed or enrolled in REPLACE
received rhPTH (1-84), 50 μg/day, escalated to 75 and then
to 100 μg/day, if required. Twenty-four patients, of which 16
previously treated with rhPTH (1-84), and 8 rhPTH (1-84)-naïve,
were enrolled and completed the study. This extension study
did not show serious adverse events, and no patients discon-
tinued because of adverse events. The most frequently
reported treatment-emergent adverse events, mild or moder-
ate in severity, such as hypocalcemia, muscle spasms, vitamin
D decrease, hypercalcemia, fatigue, headache, and hypocalce-
mia, were described. In five patients (21%), adverse events
occurred related to the drug, and all resolved within 7 days.
Three patients had rhPTH (1-84) dose reduction to 50 μg every
other day for hypercalcemia. Sustained rhPTH (1-84) efficacy
up to 48 weeks was described despite treatment interruption
between studies [13].
Rubin et al. have recently published a prospective open-
label study of 33 subjects affected by hypoparathyroidism,
treated with rhPTH (1-84) administered subcutaneously
(starting dose of 100 μg every other day) for a period of
6 years [14]. During the course of this study, a titration
schedule in which the dose could be increased or decreased
was followed. The dose was adjusted for almost all patients,
varying with a dosage of 25, 50, 75, and 100 mcg daily, at
time points ranging from 4 months to 5.5 years of treatment
(median time of dose change was 3.5 years). The experience
with the therapeutic use of PTH for 6 years has demon-
strated, although in a small sample, safety regarding the
control of calcium homeostasis. Serum calcium levels
remained in the lower end of the normal range throughout
the 6 years, and urinary calcium excretion fell significantly
below pretreatment levels at years 1, 3, and 6. No hypercal-
cemic events required hospitalization. Moreover, many
adverse events, including nausea, headache, musculoskeletal
ache, fatigue, dizziness, neurologic, mental and mood, par-
esthesia, and increased urination, were diminished after the
first year of treatment. The most common serious adverse
event was hypocalcemia (five times in three patients), and
other adverse events included eight fractures (the fracture
sites were: wrist and elbow [year 1], toe [year 2], fourth
metatarsal [year 3], wrist [year 5], and wrist, leg, and toe
[year 6]), in six patients. Other adverse events included three
episodes of nephrolithias in three patients [14]. In this study,
which is the longest clinical study with rhPTH (1-84) treat-
ment available so far in the management of hypoparathyr-
oidism, lumbar spine BMD increased as did total hip BMD,
whereas femoral neck BMD remained stable and the distal
one-third radius decreased. On the other hand, bone turn-
over markers increased significantly, reaching a 3-fold peak
above baseline values at 1 year and subsequently declining
but remaining higher than pretreatment values [14].
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During pregnancy and lactation, no adequate studies in
women for the use of rhPTH (1-84) have been carried out,
except for some animal studies. Since animal studies are not
always predictive of human response and, in fact, the effects
of rhPTH (1-84) during pregnancy and breastfeeding are
unknown, the drug should be not used in these conditions [6].
Safety and efficacy in patients <18 years of age have not
been reported, and the use of this drug is currently to be
avoided in case of pediatric and young adult patients with
open epiphyses, considering the increased baseline risk for
osteosarcoma [18]. Moreover, there are no clinical studies
that include a sufficient number of patients aged 65 and
over to determine a different response in these subjects com-
pared to younger subjects. Therefore, caution is recom-
mended in increasing the dosage of the drug in elderly
individuals [6].
rhPTH (1-84) may trigger the development of antibodies.
Among the clinical studies conducted in patients with hypopar-
athyroidism treated with rhPTH (1-84) for up to 2.6 years, the
immunogenicity incidence rate was 16.1% (14/78). Anti-PTH anti-
bodies did not appear to affect efficacy or safety during the
clinical trials, but their longer-term impact is unknown.
Moreover, it is important to remember that immunogenicity
assay results are highly dependent on the sensitivity and speci-
fics of the assay and can be influenced by several factors [6]. No
adverse events are correlated with the presence of antibodies [9].
The common adverse reactions associated with rhPTH (1-
84) in subjects affected by chronic hypoparathyroidism
described in the clinical trials are summarized in Table 2.
2.2. rhPTH (1-34) hormone replacement therapy in
chronic hypoparathyroidism and its drug safety
evaluation
From 1996 until now, some studies have analyzed varying
dose regimens of rhPTH (1-34) for the treatment of chronic
hypoparathyroidism, including once-daily and twice-daily sub-
cutaneous injections, and administration pump delivery sys-
tem in adults and children [19–24]. These studies have shown
that rhPTH (1-34) achieved better results in terms of maintain-
ing normal serum calcium compared to conventional therapy.
In particular, the studies on injections twice a day of rhPTH (1-
34) have shown a good control of calcium concentrations
compared with conventional therapy, and less fluctuation in
serum calcium levels compared with injections once a day,
associated with a total daily PTH dose, markedly reduced.
Subsequently, rhPTH (1-34) therapy delivered by an infusion
pump showed near normalization of the diurnal rhythm of
PTH, calcium and phosphate concentrations, and a significant
reduction of 24-h urinary calcium levels compared with twice-
a-day injection therapy.
Below, there is a comprehensive analysis of results on drug
safety profile among the papers published from 1998 until
now. The major findings regarding effects on serum and urin-
ary calcium levels and reduction of calcium and calcitriol
supplementation of all clinical studies conducted with rhPTH
(1-34) are summarized in Table 3.
A 28-week randomized crossover trial conducted in 17
adult patients with chronic hypoparathyroidism that com-
pared once-daily and twice-daily rhPTH (1-34) regimens
reported that four patients had bone pain during the once-
daily arm and one patient during the twice-daily arm. Nocturia
has been reported in two patients during twice-daily PTH
therapy. During the once-daily arm, two patients complained
of fatigue, but not during twice-daily therapy. Despite the
inconvenience of the second injection, 12/17 patients pre-
ferred the double-daily dosing of PTH [20].
Subsequently, Winer et al. conducted a 3-year, randomized,
open-label crossover study to establish the long-term efficacy
of twice-daily rhPTH (1-34) compared with conventional treat-
ment in 27 adults and 12 children affected by chronic hypo-
parathyroidism [21,22]. In adults, transient episodes of upper
and lower extremity cramping, numbness, and tingling
occurred unpredictably during both treatment arms, often
without apparent fluctuation in serum calcium levels. There
was no significant difference in the incidence of adverse
events, such as neuromuscular irritability, bone pain, fatigue,
or arthralgias. In seven subjects receiving rhPTH (1-34) and
three subjects receiving calcitriol therapy, mild intermittent
lower extremity bone pain occurred. Several patients reported
less fatigue and greater endurance with rhPTH (1-34), whereas
fatigue was a common complaint in the calcitriol group [20].
Children receiving rhPTH (1-34) over 3 years had stable renal
function and normal linear growth and bone accrual. Analysis
of symptom occurrence at any time during the follow-up
showed no significant differences between groups. Serious
adverse events included hypocalcemia on two occasions in a
patient with CaSR activating mutation. During the study, there
was a single report of bone pain from one child receiving
rhPTH (1–34) [1–22,34].
Recently, rhPTH (1-34) was administered as a continuous
infusion by the use of an insulin pump with multi micro-
pulses release of the peptide, in order to mimic physiologic
PTH secretion [23–25]. Winer et al. compared a pump
Table 2. Adverse reactions associated with recombinant human parathyroid
hormone (rhPTH) (1-84) in subjects with hypoparathyroidism.
N: 84 subjects
%
Paresthesia 31
Hypocalcemia 27
Headache 25
Hypercalcemia 19
Nausea 18
Hypesthesia 14
Diarrhea 12
Vomiting 12
Arthralgia 11
Hypercalciuria 11
Pain in extremity 10
Upper respiratory tract infection 8
Abdominal pain upper 7
Sinusitis 7
Blood 25-hydroxycholecalciferol decreased 6
Hypertension 6
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delivery system with twice-daily injections to further refine
replacement therapy with PTH (1-34) in adults and in chil-
dren [23,24].
The first study analyzed eight adult patients with postsur-
gical chronic hypoparathyroidism in a 6-month, open-label,
randomized, crossover trial. During this study, no serious
adverse events occurred. Between pump and twice-daily deliv-
ery, mean frequency and severity of hypocalcemic symptoms
did not differ significantly, and the frequency and severity of
symptoms were higher at baseline than during the two study
periods. Fatigue was also significantly greater between base-
line and pump delivery. At the end of the study, seven of eight
patients preferred pump to twice-daily delivery [23].
In another trial, the same group compared pump delivery
with twice-daily injections of rhPTH [1–34] in 12 children and
young adults with chronic hypoparathyroidism due to auto-
immune polyendocrine syndrome type 1 or CaSR mutation.
There were no episodes of severe tetany or seizures and no
severe hypocalcemia (or hypercalcemia) requiring emergency
treatment. At the conclusion of the study, some patients
reported preference for pump delivery because of reduced
symptoms associated with calcium fluctuations, ease of use,
and the potential long-term health benefits [24].
rhPTH [1–34] treatment, administered by twice-daily sub-
cutaneous injections, versus conventional therapy, produced a
significant increase in markers of bone turnover [21]. Mean
serum alkaline phosphatase and osteocalcin levels and mean
urinary deoxypyridinoline and pyridinoline excretion levels
were significantly higher throughout the 3-year study period
in the PTH-treated group of adult patients affected by chronic
hypoparathyroidism [21]. Subsequently, at year 3, serum
osteocalcin and urinary pyridinium cross-links showed an
apparent decrease compared with the values at year 2.5 [21].
Bone mineral content and BMD showed no significant
between-group differences over the 3-year study period. On
the other hand, the studies on use of pump delivery showed
that bone turnover markers reduced significantly compared
with twice-daily delivery [23,24]. No data exist regarding bone
quality and risk of fracture and treatment with rhPTH (1–34) in
hypoparathyroid patients.
Recently, a 2-year prospective, open-label study investi-
gated the effects of 6 months of rhPTH (1–34) treatment
(twice-daily 20 mcg daily) in 42 adult subjects with post-
surgical hypoparathyroidism, as well as evaluating quality of
life changes [26]. The mean serum calcium levels signifi-
cantly increased from baseline to 15 days and remained
stable until the end of the study, despite a significant
reduction in calcium and vitamin D supplementation. Data
derived by RAND SF-36 Health Survey showed a significant
improvement in the mean scores of all eight domains at the
Table 3. The major findings regarding effects on serum and urinary calcium levels and reduction of calcium and calcitriol supplementation of all clinical studies
conducted with rhPTH (1-34).
Authors and
year of
publication Subjects Type of study
Duration of
the study Main results
Winer et al.
1998 [20]
17 adults Randomized,
open-label crossover
once-daily rhPTH (1-34)
subcutaneous (s.c.) injections
(46 ± 32 μg) versus
twice-daily rhPTH 1-34 s.c.
(97 ± 60 μg)
28 weeks During the second half of the day (12–24 h), twice-daily rhPTH (1-34) increased
serum calcium levels more effectively than once-daily rhPTH (1-34).
Winer et al.
2003 [21]
27 adults Randomized,
open-label crossover,
twice-daily rhPTH (1-34) s.c.
injections
(37 ± 2.6 μg) versus
calcium and 1-25(OH)2 D
3 years Throughout the 3-year study period, serum calcium levels
were similar in both treatment groups within or just below
the normal range. Mean urinary calcium excretion was within
the normal range from 1 to 3 years in rhPTH (1-34)-treated patients, but
remained above normal in the calcitriol group
Winer et al.
2010 [22]
12
children
Randomized,
open-label,
twice-daily rhPTH (1-34) s.c.
injections
(0.6 ± 0.5 μg) versus
calcium and 1-25(OH)2 D
3 years Mean predose serum calcium levels were maintained at, or just below, the
normal range, and urine calcium levels remained in the normal range
throughout the 3-year study, with no significant differences between
treatment groups.
Winer et al.
2012 [23]
8 adults Open-label crossover
via pump rhPTH (1-34) s.c.
injections (13 ± 4 μg/d) versus
twice-daily rhPTH 1-34 s.c.
injections
(37 ± 14 μg/d)
24 weeks Pump versus twice-daily delivery of rhPTH (1-34) produced less fluctuation in
serum calcium levels, a more than 50% reduction in urine calcium levels,
and a 65% reduction in the PTH dose to maintain normal serum calcium
levels
Winer et al.
2014 [24]
12
children
and
adults
Randomized,
open-label crossover
via pump rhPTH (1-34) s.c.
injections (0.32 μg/Kg/d) versus
twice-daily rhPTH 1-34 s.c.
injections
(0.85 μg/Kg/d)
13 weeks rhPTH (1-34) delivered via pump produced near normalization of mean serum
calcium, and normalized mean urine calcium excretion. Serum and urine
calcium showed a biphasic pattern during twice-daily injection versus
minimal fluctuation during pump delivery. The rhPTH (1-34) dosage was
markedly reduced during pump delivery
Santonati et al.
2015 [26]
42 adults Prospective, open-label study,
once-daily rhPTH (1-34) 20 μg s.c.
injections
2 years Decrease of total dose of calcium and calcitriol supplementation.
Serum calcium concentration remained stable in the normal range. The
daily urinary excretion of calcium
increased slightly, but not significantly, after 3 months of
therapy, and then it returned to baseline values
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end of the study, but this study did not have a control
group [26].
Regarding immunogenicity, in a clinical trial conducted in
women with osteoporosis, antibodies that cross-reacted with
rhPTH (1-34) were detected in 3% of women (15/541) treated
with this drug. Antibodies were usually first detected following
12 months of treatment and diminished after withdrawal from
therapy. No hypersensitivity reactions or allergic reactions among
these patients were described, and antibody formation did not
appear to have effects on serum calcium, or on BMD response [27].
2.3. Risk of osteosarcoma
The occurrence of osteosarcoma has been described in a study
on rats treated with PTH given subcutaneously at doses of 10,
50, and 150 μg/Kg/day [28]. The doses of PTH were, respec-
tively, 3–71 times higher than systemic exposure described in
humans following a subcutaneous dose of 100 μg/day based
on AUC. Moreover, bone metabolism in the rat differs from
that in humans, and the different physiology may account for
the increased incidence of osteosarcoma in rats [29]. With over
10 years of clinical post-approval experience with rhPTH (1–34)
and 7 years with rhPTH (1-84) for treatment of osteoporosis,
no adverse signals of osteosarcoma have been reported
[29,30]. No skeletal malignancies have been described by
clinical trials with cumulative numbers of 16,000 subjects trea-
ted with up to 3 years of continuous therapy [31–33].
3. Conclusions
In summary, regarding data on the safety of rhPTH (1-84), the
pivotal trial REPLACE has not shown significant differences
between the PTH group and the placebo group in mean
cardiovascular variables, including blood pressure, heart rate,
or QTc (corrected QT) interval, or renal variables, such as
serum creatinine or estimated creatinine clearance with this
therapy [12]. Compliance with injection was excellent for both
groups. Despite substantial decreases in supplemental calcium
and vitamin D requirements, rhPTH (1-84) was associated with
fewer clinical symptoms of hypocalcemia during maintenance
than was placebo. Only one serious adverse event in the PTH
group, characterized by hypercalcemia requiring a brief hospi-
tal stay, was regarded as treatment-related. Subsequently, the
extension study REPEAT did not show serious adverse events
[13]. Finally, the longest experience with the therapeutic use
of rhPTH (1-84) for 6 years demonstrated, although in a small
sample, safety regarding the control of calcium homeostasis,
without severe hypercalcemic or hypocalcemic events [14].
Regarding fracture events reported, it is unknown whether
the fractures that have been observed are part of the natural
history of hypoparathyroidism or attributable to rhPTH (1-84)
treatment. Data on comorbidities, such as risk of fractures in
patients with chronic hypoparathyroidism, are sparse.
However, a recent Danish case finding study identifying
patients with postsurgical hypoparathyroidism showed that
hypoparathyroid patients did not have an increased risk of
fracture compared with controls [34]. On the other hand,
another study observed, in a cohort of 104 patients with
idiopathic hypoparathyroidism and 64 healthy controls, that
vertebral fractures occurred in 18.3% patients with idiopathic
hypoparathyroidism and in 4.7% of controls. Despite increased
BMD, prevalence of vertebral fractures was higher in patients
with idiopathic hypoparathyroidism [35]. Therefore, further
data regarding risk of fractures in hypoparathyroid patients
are necessary. It is known that chronic hypoparathyroidism is a
state of low bone turnover with an increased BMD. This parti-
cular state is ‘reversed’ by administration of rhPTH (1-84),
causing a marked increase in bone turnover with an increased
number of Haversian canals per unit area in cortical bone, and
a decreased trabecular thickness and trabecular bone tissue
density. Moreover, a higher connectivity density in trabecular
bone, as evaluated by micro-computed tomography per-
formed on iliac crest bone biopsies of patients with hypopar-
athyroidism into 24 weeks of treatment with rhPTH (1-84)
100 µg/day compared to placebo, and an increased trabecular
volumetric BMD, as assessed by quantitative computed tomo-
graphy were described. In some patients, rhPTH (1-84) treat-
ment causes trabecular tunneling [36]. The decrease of BMD
described at the distal one-third radius is compatible with the
known effects of PTH to increase cortical porosity and endo-
steal resorption, but it is possible that salutary effects on
microarchitecture and bone size could provide biomechanical
advantages at cortical bone [14]. It can be hypothesized that
the marked increase in bone turnover may induce a renewal of
the overmineralized bone that is typically described in case of
chronic hypoparathyroidism; however, further investigation on
the effects of long-term treatment with PTH replacement
therapy in patients with hypoparathyroidism on bone is
needed to determine effects on bone quality and strength.
In this regard, more data are also needed from long-term bone
biopsies in order to understand the real implications of the
BMD changes.
Currently, rhPTH (1-84) is available through a restricted
program under a Risk Evaluation and Mitigation Strategy and
carries a ‘black box warning.’ It is unknown whether long-term
therapy may also cause osteosarcoma in humans, but because
of a potential risk, rhPTH (1-84) is only recommended for use
in patients whose hypocalcemia cannot be controlled by cal-
cium supplementation and active forms of vitamin D, and for
whom the potential benefits are considered to outweigh this
potential risk [6].
Finally, the studies on subcutaneous injections twice a day
of rhPTH (1–34) have shown good control of calcium concen-
trations compared with conventional therapy, and less fluctua-
tions in serum calcium levels compared with injections once a
day [20–22]. However, so far, injections once- or twice-a-day
therapy with rhPTH (1-34) have not been shown to be able to
induce a significant reduction in 24-h urinary calcium com-
pared to conventional therapy. The studies, conducted for 3
years to establish the long-term efficacy of twice-daily rhPTH
[1–34] compared with conventional treatment, in 27 adults
and 12 children affected by hypoparathyroidism, did not
show significant differences in the incidence of adverse
events, between both treatment arms, and compared with
the group treated with conventional therapy produced a sig-
nificant increase in markers of bone turnover [21,22]. The
study with rhPTH (1-34) therapy delivered by an infusion
pump showed near normalization of the diurnal rhythm of
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PTH, calcium, phosphate concentrations, and markers of bone
turnover, and a significant reduction of 24-h urinary calcium
levels compared with twice-a-day injection therapy with
rhPTH (1-34) [24]. No episodes of severe tetany or seizures
and no severe hypocalcemia (or hypercalcemia) requiring
emergency treatment during the study were described [24].
No studies have reported the development of skeletal malig-
nancies. Further studies on the effect of therapy with rhPTH (1-
34) on BMD changes, bone quality, and risk of fracture should
be performed.
4. Expert opinion
Research done in this field so far has shown that replacement
treatment with rhPTH is an attractive option for subjects
affected by chronic hypoparathyroidism who are unable to
maintain stable and safe serum and urinary calcium levels.
Both rhPTH (1-84), administered by injection once a day, and
rhPTH (1-34), especially delivered by an infusion pump, reduce
the supplementation of calcium and vitamin D required, main-
taining normal serum calcium. However, rhPTH (1-34)] has not
been approved by the FDA for treatment of chronic hypopar-
athyroidism. rhPTH (1-84) can be considered more attractive
than rhPTH (1-34) as a replacement hormone therapy, because
the full-length peptide is exactly what is missing in this dis-
ease, and its effective half-life is longer than rhPTH (1-34).
Moreover, the studies on rhPTH (1-84) for treatment of hypo-
parathyroidism have been conducted with a longer duration
and with more patients compared with studies conducted
with rhPTH (1-34). The FDA approval of rhPTH (1-84) in the
USA is an important step in the new therapeutic management
of this disease, which sometimes presents very difficult ther-
apeutic clinical management. Data in cohorts of subjects trea-
ted with rhPTH (1-84) for 4–6 years [11,14] have not raised any
safety concerns, although additional long-term data are
necessary.
The risk of osteosarcoma will have to be analyzed and
monitored in the next long-term studies of chronic treatment
with rhPTH (1-84), though the use of rhPTH (1-34), introduced
as a treatment for osteoporosis in 2002, has not yet revealed
information that might suggest a higher risk of this tumor
compared to the general population, as well as the longest
experience with the therapeutic use of rhPTH (1–84) of 6 years.
During the first few months of treatment with rhPTH, hyper-
calcemia can occur, but it is readily corrected with titration of
the patient’s supplementation regimen, therefore, this does
not appear to be an important issue for this type of treatment.
Many adverse events, including nausea, headache, musculos-
keletal ache, fatigue, dizziness, neurologic, mental and mood
alterations, paresthesia, and increased urination, tend to
decrease during treatment with rhPTH (1-84) [14]. Moreover,
studies usually show good compliance, optimal tolerance, and
high tolerance to the drug (1-84). However, since therapy with
rhPTH is a long-term management option in hypoparathyroid-
ism, more long-term safety data are needed.
In the coming years, further studies are needed regarding
the effects of rhPTH therapy on hypercalciuria and clinically
relevant renal complications, such as renal impairment,
nephrocalcinosis and nephrolithiasis, or other ectopic calcifi-
cations. In addition, the long-term effect on BMD, bone
quality, and the risk of bone fractures must be clarified.
Other delivery systems of rhPTH, not requiring subcutaneous
injection, could be investigated to further increase patient
compliance to therapy. Moreover, studies regarding more
physiologic delivery systems and ideal dosing could be use-
ful, because therapies with rhPTH still cannot exactly mimic
the physiological PTH levels and calcium-phosphate home-
ostasis. Moreover, doses of rhPTH should be graded accord-
ing to age/weight of the patient and, above all, based on the
therapeutic response, in order to avoid, as much as possible,
physiological fluctuations in levels of PTH, calcium, and phos-
phorus. Regarding the effects of rhPTH (1-84) on quality of
life, in literature, there are limited and conflicting data with
each other [15,16], thus, further placebo-controlled studies
should be conducted to analyze this aspect on large samples
and with long follow-up. Probably, adequate and specific
questionnaires should be created to assess accurately all
aspects involved in quality of life of these patients.
Future trials with rhPTH in children with developing skele-
tons affected by chronic hypoparathyroidism are necessary. In
addition, future clinical studies will have to determine whether
subjects aged 65 and over respond to treatment with rhPTH in
a different manner than younger subjects.
Finally, long-term studies on rhPTH (1–34) are necessary,
like those that have been conducted for rhPTH (1-84), and a
study that compares both drugs could clarify the differences
between them.
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